Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man

Journal of Pharmaceutical Sciences

Volumn 91, Issue 11, 2002, Pages 2441-2451

  Mager, Donald E ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Corticosteroids; Glucocorticoids; Human; Mathematical modeling; Molecular modeling; Pharmacodynamics; Pharmacokinetics; QSAR; QSPKR; Quantitative structure activity relationships; Quantitative structure pharmacokinetic relationships

Indexed keywords

BETAMETHASONE; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUNISOLIDE; FLUOCORTOLONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; MOLECULAR MODEL; NORMAL HUMAN; PHARMACODYNAMICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION;

EID: 0036828220     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10231     Document Type: Article

References (50)

1. Hansch C, Leo A. 1995. Exploring QSAR. Fundamentals and Applications in Chemistry and Biology. Washington: American Chemical Society.
2. Mayer JM, van de Waterbeemd H. 1985. Development of quantitative structure-pharmacokinetic relationships. Environ Health Perspect 61:295-306.
3. Seydel JK, Schaper KJ. 1981. Quantitative structure-pharmacokinetic relationships and drug design. Pharmacol Ther 15:131-182.
4. Fouchecourt MO, Beliveau M, Krishnan K. 2001. Quantitative structure-pharmacokinetic relationship modelling. Sci Total Environ 274:125-135.
5. Hansch C, Fujita T. 1964. Rho-sigma-pi analysis. A method for the correlation of biological activity and chemical structure. J Am Chem Soc 86:1616-1626.
6. Toon S, Rowland M. 1983. Structure-pharmacokinetic relationships among the barbiturates in the rat. J Pharmacol Exp Ther 225:752-763.
7. Hinderling P, Schmidlin O, Seydel J. 1984. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. J Pharmacokinet Biopharm 12:263-287.
8. Hinderling P. 1988. Drug distribution in the body: In vitro prediction and physiological interpretation. Prog Pharmacol 6:1-29.
9. Blakey G, Nestorov I, Arundel P, Aarons L, Rowland M. 1997. Quantitative structure-pharmacokinetics relationships: I. Development of a wholebody physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokinet Biopharm 25:277-313.
10. Nestorov I, Aarons L, Rowland M. 1998. Quantitative structure-pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity. J Pharmacokinet Biopharm 26:521-545.
11. DeJongh J, Verhaar HJ, Hermens JL. 1997. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 72:17-25.
12. Yang RS, Thomas RS, Gustafson DL, Campain J, Benjamin SA, Verhaar HJ, Mumtaz MM. 1998. Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling. Environ Health Perspect 106(Suppl 6):1385-1393.
13. Gobburu J, Shelver W. 1995. Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. J Pharm Sci 84:862-865.
14. Erb R. 1993. Introduction to backpropagation neural network computation. Pharm Res 10:165-170.
15. Van der Graaf PH, Nilsson J, Van Schaick EA, Danhof M. 1999. Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat. J Pharm Sci 88:306-312.
16. Draper NR, Smith H. 1981. Applied Regression Analysis. New York: John Wiley & Sons, Inc.
17. Geladi P, Kowalski B. 1986. Partial least-squares regression: A tutorial. Anal Chim Acta 185:1-17.
18. Mollmann H, Balbach S, Hochhaus G, Barth J, Derendorf H. 1995. Pharmacokinetic-pharmacodynamic correlations of corticosteroids. In: Derendorf H, Hochhaus G, editors. Handbook of Pharmacokinetic/Pharmacodynamic Correlation. Boca Raton: CRC Press, Inc., pp 323-361.
19. Derendorf H, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Sourgens H, Erdmann M. 1995. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 35:302-305.
20. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J. 1998. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101:S440-S446.
21. Kelly HW. 1998. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 102:S36-S51.
22. Dewar M, Zoebisch E, Eamonn F, Stewart J. 1985. AM1: A new general purpose quantum mechanical molecular model. J Am Chem Soc 107:3902-3909.
23. Connolly ML. 1983. Analytical molecular surface calculation. J Appl Crystallogr 16:548-558.
24. Meylan WM, Howard PH. 1995. Atom/fragment contribution method for estimating octanol-water partition coefficients. J Pharm Sci 84:83-92.
25. Hansch C, Leo A. 1995. Exploring QSAR. Hydrophobic, Electronic, and Steric Constants. Washington: American Chemical Society.
26. Palm K, Stenberg P, Luthman K, Artursson P. 1997. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14:568-571.
27. Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
28. Derendorf H, Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M. 1991. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 31:473-476.
29. Koopmans RP, Braat MC, Oosterhuis B, van Boxtel CJ. 1992. Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model. J Pharmacol Exp Ther 262:503-508.
30. Chakraborty A, Krzyzanski W, Jusko WJ. 1999. Mathematical modeling of circadian cortisol concentrations using indirect response models: Comparison of several methods. J Pharmacokinet Biopharm 27:23-43.
31. Rohatagi S, Bye A, Mackie AE, Derendorf H. 1996. Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur J Pharm Sci 4:341-350.
32. Derendorf H, Hochhaus G, Mollmann H, Barth J, Krieg M, Tunn S, Mollmann C. 1993. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol 33:115-123.
33. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E Jr, Ferry JJ, Jusko WJ. 1993. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 54:402-414.
34. Zareie M, Brattsand R, Sherman PM, McKay DM, Perdue MH. 1999. Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology. J Pharmacol Exp Ther 289:1245-1249.
35. Wolff ME, Hansch C. 1973. Correlation of physicochemical parameters and biological activity in steroids. 9 alpha-substituted cortisol derivatives. Experientia 29:1111-1113.
36. Coburn RA, Solo AJ. 1976. Quantitative structure-activity relationships among steroids. Investigations of the use of steric parameters. J Med Chem 19:748-754.
37. Wolff ME, Baxter JD, Kollman PA, Lee DL, Kuntz ID, Bloom E, Matulich DT, Morris J. 1978. Nature of steroid-glucocorticoid receptor interactions: Thermodynamic analysis of the binding reaction. Biochemistry 17:3201-3208.
38. Jusko WJ, Ludwig EA. 1992. Corticosteroids. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied Pharmacokinetics, 3rd Ed. Vancouver: Applied Therapeutics, Inc.
39. Ponec M, Kempenaar J, Shroot B, Caron JC. 1986. Glucocorticoids: Binding affinity and lipophilicity. J Pharm Sci 75:973-975.
40. Hogger P, Rohdewald P. 1998. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother 9:501-522.
41. Camilleri P, Watts SA, Boraston JA. 1988. A surface area approach to determination of partition coefficients. J Chem Soc Perkin Trans 2:1699-1707.
42. Davis AM, Webborn PJ, Salt DW. 2000. Robust assessment of statistical significance in the use of unbound/intrinsic pharmacokinetic parameters in quantitative structure-pharmacokinetic relationships with lipophilicity. Drug Metab Dispos 28:103-106.
43. Wilkinson GR, Shand DG. 1975. Commentary: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
44. Gibaldi M, McNamara PJ. 1978. Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol 13:373-380.
45. MacKichan JJ. 1992. Influence of protein binding and use of unbound (free) drug concentrations. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied Pharmacokinetics, 3rd Ed. Vancouver: Applied Therapeutics, Inc.
46. Ebling WF, Milsap RL, Szefler SJ, Jusko WJ. 1986. 6 alpha-Methylprednisolone and 6 alpha-methylprednisone plasma protein binding in humans and rabbits. J Pharm Sci 75:760-763.
47. Bohl M. 1992. Theoretical investigations on steroid structure and quantitative structure-activity relationships. In: Bohl M, Duax WL, editors. Molecular Structure and Biological Activity of Steroids. Boca Raton: CRC Press, Inc., pp 91-155.
48. Kelder J, Grootenhuis P, Bayada D, Delbressine L, Ploemen J. 1999. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 16:1514-1519.
49. Stenberg P, Luthman K, Ellens H, Lee C, Smith P, Lago A, Elliott J, Artursson P. 1999. Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharm Res 16:1520-1526.
50. Gobburu J, Jusko W. 1998. Role of dosage regimen in controlling indirect pharmacodynamic responses. Adv Drug Del Rev 33:221-233.